Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II

On May 19, 2020 Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, reported that preclinical data for NT219, a novel agent addressing treatment resistance in advanced cancer, will be presented in a poster at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Virtual Meeting II (Press release, Kitov Pharmaceuticals , MAY 19, 2020, View Source [SID1234558280]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, titled, "NT219, a novel dual inhibitor of STAT3 and IRS1/2, demonstrates anti-tumor activity with and without cetuximab in pembrolizumab-resistant head and neck cancer PDX models," includes preclinical data on NT219, a first-in-class, dual inhibitor of signal transducer and activator of transcription 3 (STAT3) and insulin receptor substrate 1 and 2 (IRS1/2), which have been associated with treatment resistance in a variety of cancer settings. Using multiple patient derived xenograft (PDX) models of subjects with head and neck squamous cell carcinoma (HNSCC), NT219 demonstrated growth inhibition, both as monotherapy (3/6 mice), as well as in combination with cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, or pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor (5/6 mice). Notably, in one study of a PDX model of a recurrent/metastatic HNSCC sample that was resistant to radiation, various chemotherapies and pembrolizumab, utilizing NT219 alone resulted in tumor growth inhibition (TGI) of 69% (p=0.017). Moreover, while cetuximab alone was not effective (TGI=17%), the combination of cetuximab with NT219 showed synergistic effect and induced regression of all tumors (p=0.001).

"These encouraging preclinical data strongly suggest that the inhibition of the STAT3 and IRS-AKT pathways has the potential to address the tumor resistance phenotype," said Isaac Israel, Chief Executive Officer of Kitov. "Based on the significant compelling preclinical evidence generated in various studies with NT219, including these data, our planned Phase 1/2 trial of NT219 will evaluate our promising product candidate both as a monotherapy treatment in patients with advanced solid tumors and in combination with cetuximab in patients with HNSCC. We look forward to initiating this Phase 1/2 trial soon."

Presentation Details:

Title: NT219, a novel dual inhibitor of STAT3 and IRS1/2, demonstrates anti-tumor activity with and without cetuximab in pembrolizumab-resistant head and neck cancer PDX models
Date: June 22, 2020
Abstract: View Source!/9045/presentation/2911

VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

On May 19, 2020 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, reported that it intends to offer and sell shares of its common stock in an underwritten public offering (Press release, VolitionRX, MAY 19, 2020, View Source [SID1234558297]). Volition intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover overallotments, if any. All shares of common stock in the offering are being offered by Volition. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NASDAQ:NHLD), is acting as sole book-running manager in connection with the offering.

Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes, including potential strategic acquisitions.

The securities described above are being offered by Volition pursuant to a "shelf" registration statement on Form S-3 (File No. 333-227248) previously filed with and declared effective by the Securities and Exchange Commission ("SEC") on September 28, 2018. A preliminary prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at View Source When available, electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: National Securities Corporation, 200 Vesey St., 25th Floor, New York, NY 10281, by telephone at (212) 417-3634 or by email at [email protected].

Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that Volition has filed with the SEC that are incorporated by reference in the preliminary prospectus supplement and the accompanying prospectus, which provide more information about Volition and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering will be made only by means of a written prospectus and prospectus supplement that form part of the registration statement.

Pfizer Prices $4,000,000,000 Debt Offering

On May 19, 2020 Pfizer Inc. (NYSE: PFE) reported the pricing of a debt offering consisting of four tranches of notes (Press release, Pfizer, MAY 19, 2020, View Source [SID1234558281]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

$750,000,000 aggregate principal amount of 0.800% notes due 2025

$1,000,000,000 aggregate principal amount of 1.700% notes due 2030

$1,000,000,000 aggregate principal amount of 2.550% notes due 2040

$1,250,000,000 aggregate principal amount of 2.700% notes due 2050

Pfizer intends to use the net proceeds for general corporate purposes, including to repay a portion of its outstanding commercial paper and/or to refinance, redeem or repurchase existing debt.

The closing of the offering is expected to occur on May 28, 2020, subject to satisfaction of customary closing conditions.

Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering.

The offering of these securities is being made only by means of a prospectus. Copies may be obtained by calling Barclays Capital Inc. at (888) 603-5847, Citigroup Global Markets Inc. at (800) 831-9146, Deutsche Bank Securities Inc. at (800) 503-4611 and J.P. Morgan Securities LLC at (212) 834-4533.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the notes, nor will there be any sale of the notes in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

Nordic Nanovector ASA: Invitation to First Quarter 2020 Results Webcast

On May 19, 2020 Nordic Nanovector ASA (OSE: NANO) reported that it will report its results for the first quarter 2020 on Tuesday, 26 May 2020 (Press release, Nordic Nanovector, MAY 19, 2020, View Source [SID1234558298]). A presentation by Nordic Nanovector’s senior management team will take place via a webcast at 08:30 am CET on the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A link to the webcast and a presentation will be uploaded to the company’s homepage (www.nordicnanovector.com) at 07:00 am CET on Tuesday 26 May.

Min Jeong-jun’s Chonnam National University research team opens new horizons in malignant melanoma diagnosis and treatment

On May 19, 2020 Chonnam National University College of Medicine reported the company’s research team has developed an ultra-sensitive PET molecular imaging probe that can sensitively detect metastatic lesions of malignant melanoma (Press release, CNCure, MAY 19, 2020, View Source [SID1234649030]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Professor Min Jeong-jun and Dr. Kim Dong-yeon’s research team at Chonnam National University developed a new molecular imaging precision diagnostic technology by utilizing the chemical structure called benzamide, which can bind to melanin molecules secreted by malignant melanoma.

We synthesized a novel structure that can enhance the targeting ability and uptake rate of malignant melanoma through chemical methods and produced an imaging probe labeled with the positron-emitting nuclide 18F.

This compound, named [18F]DMPY2, showed significantly higher cancer-specific uptake and rapid excretion than previously reported imaging probes.

In particular, results evaluated in small animals showed that it sensitively detects not only primary malignant melanoma but also small cancer metastases less than 1 mm in size, showing superior diagnostic performance and biological characteristics than PET imaging probes currently undergoing clinical trials in the United States.

The research team has registered a domestic patent for this technology and applied for an overseas patent. The technology has been transferred to CNCure, a company founded by the researchers, and is currently preparing for clinical trials.

[18F]DMPY2 showed the highest tumor uptake among melanoma targeting drugs reported so far, with approximately 25% of the injected dose being taken up by malignant melanoma.

This means that there is a very good chance that this imaging technology will be used to diagnose malignant melanoma in humans in the near future.

In addition, if the structural characteristics of DMPY2 are maintained while successfully conjugating a therapeutic radionuclide, it is highly likely that this will lead to the development of a new radiopharmaceutical for the targeted treatment of malignant melanoma.

The research team is developing a theranostic agent that can be used for both diagnosis and treatment based on the DMPY2 structure.

This study was conducted with the support of the Ministry of Science and ICT’s Future Promising Convergence Technology Pioneer Project and the Ministry of Health and Welfare’s Health and Medical Technology Research and Development Project, and the paper was published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS, 5-year impact factor: 10.600) on May 19, 2020.

The title of the paper is ‘Ultrasensitive detection of malignant melanoma using PET molecular imaging probes’ and the authors are Professor Min Jeong-jun (corresponding author, Chonnam National University), Dr. Kim Dong-yeon (corresponding author, Chonnam National University Hwasun Hospital), and Dr. Pyo Ah-young (first author, Chonnam National University).

Malignant melanoma is a very aggressive and highly lethal skin cancer. If diagnosed early, it can be surgically removed, but once it has metastasized, the mortality rate within one year is 75%, so early diagnosis is the only effective way to increase the patient’s survival rate.

Professor Min Jeong-jun said, "This study not only proves that the approach and results are excellent, but also means that there is a very high possibility that this diagnostic technology will be used to diagnose malignant melanoma in humans in the near future." He added, "We look forward to more research on the treatment of malignant melanoma in the future, as we can develop new substances that can not only diagnose but also treat malignant melanoma."